Figure 4

Early phase effects of Tlx1 overexpression in situ in the spleen on hematopoietic factor expression and behavior of HSPCs. (a) Schematic of the experimental strategy represents time points of the analyses for hematopoietic factor mRNA and serum G-CSF as well as peripheral blood HSPCs. Data were pooled from 2–3 independent experiments. (b) Expression of the indicated hematopoietic factor mRNA in Venus⁺ cells of the spleen from tamoxifen-treated Tlx1^CreER-Venus controls (Ctr) and tamoxifen-treated Tlx1^CreER-Venus; R26^Tlx1 mice (Tg). (mean ± SD, n = 3). The relative mRNA levels were normalized to β-actin and the level of mRNA transcripts in Venus⁺ cells of tamoxifen-treated Tlx1^CreER-Venus controls was arbitrarily set to 1. (c) Serum G-CSF concentration of tamoxifen-treated Tlx1^CreER-Venus controls (Ctr) and tamoxifen-treated Tlx1^CreER-Venus; R26^Tlx1 mice (Tg). (mean ± SD, n = 5). (d) Total numbers of the indicated HSPC populations in the peripheral blood of tamoxifen-treated Tlx1^CreER-Venus controls (Ctr) and tamoxifen-treated Tlx1^CreER-Venus; R26^Tlx1 mice (Tg). (mean ± SD, n = 5–7). (e) Total cell numbers of transplanted CD45.1 LSK cells in the spleen and BM of tamoxifen-treated Tlx1^CreER-Venus controls (Ctr) and tamoxifen-treated Tlx1^CreER-Venus; R26^Tlx1 mice (Tg). (mean ± SD, n = 5–6). (f) The frequency of BrdU-incorporated LSK and LK cells in the spleen and BM of tamoxifen-treated Tlx1^CreER-Venus littermate controls (Ctr) and tamoxifen-treated Tlx1^CreER-Venus; R26^Tlx1 mice (Tg). (mean ± SD, n = 3–5).